Registries as a tool in evidence‐based medicine: example of KIMS (Pfizer International Metabolic Database)
Authors:
- Lia P. GutiérrezLGLia P. Gutiérrez
- Maria Kołtowska‐HäggströmMKMaria Kołtowska‐Häggström
- Peter J. JönssonPJPeter J. Jönsson
- Dag SvenssonDSDag Svensson
- 24 October 2007
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 17 (1) , 90-102
Abstract
Purpose: To evaluate the value of a registry, set in ‘real‐life practice’, as a contribution to evidence‐based medicine and to estimate the impact of information collected in such a registry, on the up to date knowledge in growth hormone (GH)‐related disorders.Methods: Analysis of data collected prospectively for a pharmacoepidemiological registry—KIMS (Pfizer International Metabolic Database)—in assessing long‐term clinical and safety outcomes of GH treatment (Genotropin®) in patients with GH deficiency. The study was based on 11 374 treated (40 000 patient‐years of observation) and 263 untreated adult GH deficient patients from 30 countries, in whom background characteristics, clinical values such as lipids and body composition, quality of life (QoL) and GH dosage as well as safety profile were evaluated. Citation analysis for the published papers was also performed.Results: The study depicts the clinical picture of adult patients with GH deficiency managed in current clinical settings. It confirms the features previously detected such as increased cardiovascular risk, mostly dyslipidemia and abnormal body composition as well as impaired QoL. There was considerable heterogeneity of conditions resulting in GH deficiency. The large database also enabled study of rare causes of the condition. The 31 out of 36 KIMS papers were cited 544 times, in 125 different journals.Conclusions: These findings and the further insight into the response to GH replacement therapy show that the registry methodology is valuable for filling the gaps of information in evidence‐based medicine that cannot be addressed by clinical trials. Copyright © 2007 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- Baseline characteristics and response to GH replacement of hypopituitary patients previously irradiated for pituitary adenoma or craniopharyngioma: data from the Pfizer International Metabolic DatabaseEuropean Journal of Endocrinology, 2006
- Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?European Journal of Endocrinology, 2006
- Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults – a KIMS database analysisEuropean Journal of Endocrinology, 2006
- Long-Term Challenges in Growth Hormone TreatmentHormone Research in Paediatrics, 2004
- Determinants of IGF‐I status in a large cohort of growth hormone‐deficient (GHD) subjects: the role of timing of onset of GHDClinical Endocrinology, 2003
- Thirty Years of Bioethics: The Helsinki Declaration 1964-2003New Review of Bioethics, 2003
- Growth hormone deficiency and replacement in elderly hypopituitary adultsClinical Endocrinology, 2000
- Growth Hormone Replacement Therapy Is Not Associated with Any Increase in MortalityThe Journal of Clinical Endocrinology & Metabolism, 1999
- Contribution of trends in survival and coronar y-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populationsThe Lancet, 1999
- Premature mortality due to cardiovascular disease in hypopituitarismThe Lancet, 1990